AlphaStreet Newsdesk powered by AlphaStreet Intelligence
ALT|EPS -$0.12 vs -$0.14 est (+14.3%)|Rev $0|Internet Loss $22.8MAltimmune, Inc. (ALT) posted a Q2 2026 fundamental and diluted lack of $0.12 per share, narrower than the -$0.14 anticipated loss (14.3% narrower). The lack of $0.12 per share narrowed 55.6% from the $0.27 loss in Q2 2025.
Income totaled $0 for the quarter. Income was down 100.0% from $5,000 in Q2 2025.
Altimmune, Inc. is a Biotechnology firm. Backside line confirmed a web lack of $22.8M.
Wall Avenue consensus stands at 9 purchase, 2 maintain, 0 promote.
This content material is for informational functions solely and shouldn’t be thought of funding recommendation. AlphaStreet Intelligence analyzes monetary information utilizing AI to ship quick and correct market info. Human editors confirm content material.
